Filing Flows › Rigel Pharmaceuticals (RIGL) › Net income
Rigel Pharmaceuticals (RIGL) net income by quarter
Rigel Pharmaceuticals' net income was $13.2M in Q3 2026 (third quarter 2026), -24% from Q2 2026. Over the last 7 quarters it ranged from $8.7M (Q1 2026) to $268M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $13.2M | -24% | -53% |
| Q2 2026 | $17.3M | +100% | -71% |
| Q1 2026 | $8.7M | -97% | -24% |
| Q4 2025 | $268M | +861% | — |
| Q3 2025 | $27.9M | -53% | — |
| Q2 2025 | $59.6M | +421% | — |
| Q1 2025 | $11.4M | — | — |
Q3 2026 at a glance
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rigel Pharmaceuticals' net income?
Rigel Pharmaceuticals' net income was $13.2M in Q3 2026 (third quarter 2026), -24% from Q2 2026.
How has Rigel Pharmaceuticals' net income changed?
Over the last 7 quarters it ranged from $8.7M (Q1 2026) to $268M (Q4 2025).